Also listed under Basal Ganglia Diseases, Chorea, Cognition Disorders, Dementia
ClinicalTrials.gov term: Huntington Disease
Huntington's Disease clinical trials
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19
What changed in the last 30 days
3 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 2 with minor changes only.
- Minor: SRP-1005 · Huntington's Disease Trial sites expanded: 4 → 8 locations
- Notable: Rollover Study for Continuing Valbenazine Administration · Chorea Associated With Huntington Disease Reclassified as terminated (was completed)
- Minor: DANNIgene · Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders Study completion pushed from May 2027 to Jun 2028
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New sponsor entrants, last 90 days sponsors with their first trial in this area
| First posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-10-28 | NCT07902206 Creatine and Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation Plus Home-Based… | Universidad de Burgos new |
Active trials by phase
| Early Phase 1 | 1 | |
| Phase 1 | 4 | |
| Phase 1/2 | 7 | |
| Phase 2 | 5 | |
| Phase 2/3 | 4 | |
| Phase 3 | 3 |
Not charted: 43 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Top sponsors by active trials in this area
Assistance Publique - Hôpitaux de Paris (3) · Hoffmann-La Roche (3) · Skyhawk Therapeutics, Inc. (3) · University of Central Florida (3) · CHDI Foundation, Inc. (2) · Novartis Pharmaceuticals (2) · UniQure Biopharma B.V. (2) · Universitaire Ziekenhuizen KU Leuven (2) · University Hospital, Angers (2) · Alnylam Pharmaceuticals (1)
Get alerts when Huntington's Disease trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.